Ophthalmologic irrigation solutions and method
US-9278101-B2 · Mar 8, 2016 · US
Ophthalmologic irrigation solutions and method
US9399040B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9399040-B2 |
| Application number | US-201314075588-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 8, 2013 |
| Priority date | Jul 30, 2002 |
| Publication date | Jul 26, 2016 |
| Grant date | Jul 26, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.
First claim
Opening claim text (preview).
The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows: 1. A composition for use in an intraocular ophthalmologic procedure, comprising an anti-inflammatory agent and a mydriatic agent in a physiologic irrigation solution for intraocular delivery, wherein the anti-inflammatory agent comprises ketorolac and the mydriatic agent comprises phenylephrine, wherein the ketorolac and phenylephrine are included at concentrations less than that used for conventional topical or systemic delivery and in a therapeutically effective amount for the maintenance of pupil dilation and inhibition of miosis during the procedure and the reduction of postoperative pain when delivered intraocularly during the intraocular ophthalmologic procedure. 2. The composition of claim 1 , wherein the wherein the ketorolac is included in the solution at a concentration of no more than 100,000 nanomolar and the phenylephrine is included in the solution at a concentration of no more than 500,000 nanomolar. 3. The composition of claim 1 , wherein the pH of e irrigation solution is between 5.5 and 8.0.
Assignees
Inventors
Classifications
Free radical scavengers or antioxidants · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution · CPC title
without antiinflammatory effect · CPC title
Ophthalmic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9399040B2 cover?
- Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differi…
- Who is the assignee on this patent?
- Omeros Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K31/573. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).